Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mesoblast

13.55
+0.27002.03%
Post-market: 13.550.00000.00%16:05 EDT
Volume:329.44K
Turnover:4.41M
Market Cap:1.72B
PE:-15.20
High:13.58
Open:13.26
Low:13.14
Close:13.28
Loading ...

Mesoblast Financial Results and Corporate Update Webcast

GlobeNewswire
·
26 Feb

Mesoblast Ltd expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
25 Feb

Mesoblast Limited Announces New Director Appointment

TIPRANKS
·
24 Feb

Mesoblast Appoints Dr. Gregory George to Board, Strengthening Operational Expertise

TIPRANKS
·
24 Feb

Dr. Gregory George MD PhD Joins Mesoblast Board

GlobeNewswire
·
24 Feb

Mesoblast’s Ryoncil® Gains FDA Approval, Set to Revolutionize SR-aGvHD Treatment

TIPRANKS
·
14 Feb

Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value

Simply Wall St.
·
12 Feb

Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says

MT Newswires Live
·
12 Feb

Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?

Insider Monkey
·
12 Feb

Mesoblast Price Target Raised to $24.00/Share From $15.00 by Piper Sandler

Dow Jones
·
07 Feb

Mesoblast price target raised to $24 from $15 at Piper Sandler

TIPRANKS
·
07 Feb

Mesoblast's Largest Shareholder Raises Stake to Over 19%; Mesoblast Shares Up 3%

MT Newswires Live
·
07 Feb

BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares

Reuters
·
06 Feb

Mesoblast Ltd Files Prospectus Relates to Offer and Sale From Time to Time by the Shareholders of up to 34.7 Mln Ordinary Shares

THOMSON REUTERS
·
06 Feb

Why Block, Canyon, Fisher & Paykel Healthcare, and Mesoblast shares are falling today

MotleyFool
·
05 Feb

High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others

Simply Wall St.
·
04 Feb